Adamis Pharma Overview
Industry: Pharmaceuticals
Sector: Healthcare
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
Adamis Pharma is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Adamis Pharma in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Adamis Pharma Competitors
Adamis Pharma operates in the Pharmaceuticals industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans